Skip to main content
Premium Trial:

Request an Annual Quote

Proteros to Generate Leads for J&J

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteros Biostructures said today that it has agreed to investigate potential small molecule lead compounds for Johnson & Johnson Pharmaceutical Research and Development (J&JPRD).

Under the partnership agreement, Proteros will use its lead discovery service, which employs structural biology, screening of an in-house compound and fragment library, compound profiling, and medicinal chemistry activities, to find leads against a specific target provided by J&JPRD.

The Martinsried, Germany-based firm said its service speeds up protein structure analysis and structure-based discovery with its expertise and processes for crystallography and fragment-based lead generation.

Financial terms of the agreement were not released.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.